











RECEIVED

FEB 04 2002

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98) SHEET 1 OF 1 				ATTORNEY DOCKET 37522-1002P2		APPLICATION NO. TECH CENTER 1600/2900 09/866,536	
				APPLICANT(S) Peter D. Gluckman, et al.			
				INTERNATIONAL FILING DATE May 24, 2001		GROUP 1627 1639	
US PATENT DOCUMENTS							
† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)	
	A1	4,906,614	3/1990	Giertz	514/18	Equivalent to AU52601/86	
	A2	5,106,832	4/1992	Froesch, et al.	514/3		
	A3	5,273,961	12/1993	Clark	514/8		
	A4	5,686,423	11/1997	Wang	514/18		
FOREIGN PATENT DOCUMENTS							
† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)		
	B1	93/02695 ✓	2/1993	PCT	Yes		
	B2	93/21216 /	10/1993	PCT	Equivalent to AU38084/93		
OTHER DOCUMENTS							
† EX'R INITIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
	C1 ✓	Guan et al., <u>The Effects of IGF-1 Treatment After Hypoxic-Ischemic Brian Injury In Adult Rats</u> , The Journal of Cerebral Blood Flow and Metabolism, vol. 13 (1993), pp. 13:609-616.					
	C2 ✓	G. M. Shepherd, "Neurotransmitters and Neuromodulators", Neurobiology Second Edition (1988), pp. 145-176.					
	C3 ✓	Curtis D. R. et al., "Amino Acid Transmitters In The Mammalian Central Nervous System", Ergebnisse Der Physiologie, vol. 69 (1974), pp. 97-188.					
EXAMINER'S SIGNATURE B C C S A				DATE CONSIDERED 4/7/03			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).							



RECEIVED
SEP 13 2001
TECH CENTER 1600/2900
1627 1639

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98) SHEET 1 OF 1	ATTORNEY DOCKET 37522-1002P2	APPLICATION NO. 09/866,536
	APPLICANT(S) Peter D. Gluckman, et al.	
	INTERNATIONAL FILING DATE May 24, 2001	GROUP 1627 1639

US PATENT DOCUMENTS

† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
	B1	0 366 638	10/24/89	EPO	Yes
	B2	WO 95/17204	07/29/95	PCT	Yes
	B3	WO 98/14202	04/09/98	PCT	Yes

OTHER DOCUMENTS

† EX'R INITIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	C1	V. Sara, et al, "Identification of GLY-PRO-GLU (GPE), The Aminoterminal Tripeptide Of Insulin-Like Growth Factor 1 Which Is Truncated In Brain, As A Novel Neuroactive Peptide", Biochemical & Biophysical Research Communications vol. 165, no. 2, 1989, December 15, 1989 pp 766-771.
	C2	L. Nilsson-Hakansson, et al., "Effects of IGF-1, Truncated IGF-1 And The Tripeptide Gly-Pro-Glu On Acetylcholine Release From Parietal Cortex Of Rat Brain", Neuroreport, 4, 1111-1114(1993)
	C3	J. Saura, "Neuroprotective Effects Of Gly-Pro-Glu, the N-terminal Tripeptide Of IGF-1, In The Hippocampus In Vitro", Neuroreport 10, pp. 161-164 (1999).
	C4	V. Sara, "The Biological Role of Truncated Insulin-Like Growth Factor-1 and The Tripeptide GPE In The Central Nervous System", Annals of the New York Academy of Sciences vol. 692, pp 183-191 (1998)

EXAMINER'S SIGNATURE B CELSA	DATE CONSIDERED 4/7/03
-------------------------------------	-------------------------------

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).



COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 2

Form 100-1449 <i>(Substitute)</i>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket Number 091866,536 NRNZ-1002US3	Application Number 09/866,536
		Applicant Owner Gluckman, et al.	
		Filing Date 5/24/01	Group Art Unit 1639

RECEIVED

SEP 10 2002

TECH CENTER 1600/2901

U.S. PATENTS

Examiner Initial	Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
<i>///</i>	5,804,550	9/8/98	Bourguignon	514	3	

U.S. PATENT PUBLICATIONS

Examiner Initial	Patent Application Publication Number	Publication Date	Applicant

PENDING U.S. PATENT APPLICATIONS

Examiner Initial	Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No

B. CELSA

417603

109/866,536

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Trans- lation	
						Yes	No
<i>AK</i>	WO 95/17204 ✓	6/29/95	—	—	—		
<i>PL</i>	WO 98/14202 ✓	4/9/98	—	—	—		
<i>ML</i>	WO 99/65509 ✓	12/23/99	—	—	—		
<i>MC</i>	EP 0/366638	5/2/90	—	—	—		

RECEIVED

SEP 10 2002

TECH CENTER 1600/290

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)

[illegible]

Examiner B eersa

Date Considered 4/7/63

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MRP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*1 = Copy not submitted because it was submitted in prior application SN __/____, filed _____, 20____, relied on under 35 USC § 120.

*2 = Copy not submitted because it was submitted in prior application SN / , filed , 20 , relied on under 35 USC § 120.